Larotrectinib, a groundbreaking CNS-active inhibitor targeting TRKA, TRKB, and TRKC, secured accelerated approval in 2018 for the treatment of TRK fusion cancer (Figure 2). This evidence concerns the gene NTRK3 and cancer.